KA

0.7 +0.13 (+22.81%)

- · NASDAQ

Performance

-

1W

-

1M

-

3M

+2.03%

6M

-

YTD

-73.68%

1Y

Profile

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.

Technical Analysis of KA 2024-09-19

The stock indicators reflect a neutral sentiment overall, with the Moving Average Score at 50 indicating a balanced trend, while the Oscillators Score of 46 and Technical Score of 48 suggest a slight bearish inclination. This combination implies that while there is no strong momentum in either direction, caution may be warranted as the scores ho...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of KA

Created with Highcharts 11.1.000004747000100
QualityGrowthMomentumValue4

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.